Sa. Kaplan et al., COMBINATION THERAPY USING ORAL ALPHA-BLOCKERS AND INTRACAVERNOSAL INJECTION IN MEN WITH ERECTILE DYSFUNCTION, Urology, 52(5), 1998, pp. 739-743
Objectives. Intracavernosal injection with a combination of agents (ie
, phentolamine plus papaverine or alprostadil) has been used in an eff
ort to increase efficacy and reduce side effects compared with single
agents. The purpose of this pilot study was to determine the potential
role of oral alpha-blockers in combination with intracavernosal thera
py in mere with erectile dysfunction, for whom intracavernosal therapy
alone failed. Methods. Thirty-eight consecutive men with moderate to
severe erectile dysfunction on the basis of history and examination an
d with minimal or no therapeutic response to intracavernosal alprostad
il injection therapy were evaluated. All patients received daily doxaz
osin titrated to 4 mg over 3 weeks in combination with intracavernosal
therapy as needed for 12 weeks. Efficacy was assessed at 4, 8, and 12
weeks after doxazosin titration using the 15-item, self-administered
International Index of Erectile Function (IIEF) and a global efficacy
question (GEQ: Did treatment improve your erections?). Results. For th
e group, the mean baseline IIEF score before therapy was 29.7 +/- 9.8.
After intracavernosal therapy (mean dose 34.7 +/- 7.3 mu g), IIEF imp
roved to 36.1 +/- 11.4 (17.7%). After addition of doxazosin, IIEF impr
oved to 48.6 +/- 13.4, 46.4 +/- 10.9, and 51.5 +/-. 14.3 at 4, 8, and
12 weeks, respectively (P < 0.01). The GEO response improved from 25.7
% at baseline to 81.4% at 12 weeks. Overall 22 (57.9%) of 38 patients
with the combined regimen had a significant (more than 60% improvement
in IIEF) therapeutic response. Conclusions. The addition of an oral a
lpha-blocker may have a beneficial effect in patients with erectile dy
sfunction for whom intracavernosal therapy alone fails. The synergisti
c effects of vascular dilation and blockade of sympathetic inhibition
may explain this response. The potential role of alpha-blockade in syn
ergy with other agents designed to treat erectile dysfunction remains
to be determined. (C) 1998, Elsevier Science Inc. All rights reserved.